Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 8/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 7/20 | 0.49 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328029 | 0.93 | SCN10A (0.57) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL23327964 | 0.93 | SCN10A (0.58) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL30882099 | 0.93 | SCN10A (0.58) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL23327955 | 0.91 | SCN10A (0.59) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL30882100 | 0.91 | SCN10A (0.59) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL23327909 | 0.89 | SCN10A (0.56) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL23327899 | 0.89 | SCN10A (0.57) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL23327968 | 0.88 | SCN10A (0.46) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL23327960 | 0.87 | SCN10A (0.48) | SCN10ASCN2AKMOMALT1RIPK1 | |
| SCHEMBL23327932 | 0.87 | SCN10A (0.47) | SCN10ASCN2AKMOMALT1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | SCN10A 8/4885SCN2A 3/4885KMO 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.